2019 Investor Materials
2018 ANNUAL REPORT
View the below digital version of our Annual Report.
2019 PROXY STATEMENT
View the below digital version of our Proxy Statement.
You may request paper copies of the proxy materials by email, online by phone by dialing 866-648-8133.
Voting
YOUR VOTE IS IMPORTANT!
Vote online now or by phone by dialing
855-773-1622.
Annual Meeting Details
DATE:
TIME:
LOCATION:
September 5, 2019
9:00 AM Local Time
6275 Nancy Ridge Drive
Suite 110
San Diego, CA 92121
About Us
Changing the Shape of Medical Research and Practice
Organovo is a biotech platform company that has developed a leadership position with its revolutionary ability to 3D bioprint tissues with human functionality. The Company is pursuing multiple IND-track programs to develop its NovoTissues® to address a number of serious unmet medical needs in adult and pediatric populations, initially focusing on liver disease. Organovo’s first IND-track program for Alpha-1-antitrypsin deficiency recently received orphan drug designation from the FDA. In order to support its plan to initiate multiple IND-track programs, the Company is providing access to its ExVive™ in vitro tissue disease modeling platform to facilitate high value drug discovery and development collaborations. Organovo’s wholly-owned subsidiary, Samsara Sciences, provides the Company and its clients with high quality human liver and kidney cells for research applications. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Powered by Donnelley Financial Solutions
Copyright © 2019 Mediant Communications Inc. All Rights Reserved.